Resources from the same session
PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Presenter: Maha Hussain
Session: Presidential Symposium III
Resources:
Abstract
Presentation
Webcast
Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 ATTRACTION-3 Study
Presenter: Byoung Chul Cho
Session: Presidential Symposium III
Resources:
Abstract
Presentation
Webcast
Invited Discussant LBA14_PR
Presenter: Thomas Powles
Session: Presidential Symposium III
Resources:
Presentation
Webcast
Invited Discussant LBA12_PR
Presenter: Eleni Efstathiou
Session: Presidential Symposium III
Resources:
Presentation
Webcast
Invited Discussant LBA10_PR and LBA11
Presenter: Ian Chau
Session: Presidential Symposium III
Resources:
Presentation
Webcast
IMvigor130: efficacy and safety from a Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Enrique Grande
Session: Presidential Symposium III
Resources:
Abstract
Presentation
Webcast
ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
Presenter: Ghassan Abou-Alfa
Session: Presidential Symposium III
Resources:
Abstract
Presentation
Webcast
CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ronald de Wit
Session: Presidential Symposium III
Resources:
Abstract
Presentation
Webcast